多西紫杉醇二线治疗紫杉醇耐药的晚期非小细胞肺癌15例

 目的　观察紫杉醇（泰素）耐药的晚期非小细胞肺癌（NSCLC）患者接受多西紫杉醇（泰素帝）二线治疗后的疗效及毒副反应。方法　回顾性分析2005年1月至2008年5月在上海市胸科医院接受多西紫杉醇二线化学治疗的15例NSCLC患者。评价其疗效及不良反应，并随访无疾病进展时间（PFS）及总生存期（OS）。结果　15例患者的疾病控制率为66.7 %，中位无疾病进展时间为6个月，中位生存期为17.3个月，1年生存率达到63.3 %。主要不良反应包括白细胞减少8例（53.3 %），胃肠道反应8例（53.3 %），呃逆6例（40 %），均属可耐受范围。结论　多西紫杉醇二线治疗在紫杉醇耐药的晚期NSCLC患者中显示了良好疗效，且毒副反应可以耐受。

Docetaxel for 15 patients with paclitaxel-resistant advanced non-small cell lung cancer

Objective To determine the efficacy and toxicity of docetaxel in patients with paclitaxel-resistant advanced non-small cell lung cancer (NSCLC). Methods The clinical data from 15 patients with NSCLC who were admitted in the Shanghai Chest Hospital from January 2005 to May 2008 were retrospectively analyzed. The effects and toxicities of the second-line treatment were assessed. The progression-free survival time(PFS) and overall survival time(OS) were analyzed. Results The disease control rate was 66.7 %, with a progression-free survival time of 6 months, and a overall survival time of 17.3 months. The 1-year survival rate was 63.3 %. The toxic effects were as expected. Conclusion The doeetaxel-based agent is active in patients with paelitaxel-resistant advanced NSCLC.